Review of fesoterodine

Expert Opinion on Drug Safety

Volumn 10, Issue 5, 2011, Pages 805-808

  Vella, Maria ^a   Cardozo, Linda ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

bladder selective; efficacy; fesoterodine; flexible dosing; overactive bladder syndrome

Indexed keywords

CYTOCHROME P450; FESOTERODINE; PLACEBO; SOLIFENACIN; TOLTERODINE;

ARTICLE; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; DRY EYE; ELECTROCARDIOGRAM; HEADACHE; HUMAN; MICTURITION; OVERACTIVE BLADDER; QT INTERVAL; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MULTICENTER STUDIES AS TOPIC; MUSCARINIC ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER, OVERACTIVE;

EID: 80051979127     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.591377     Document Type: Article

References (14)

1. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct 2010;21(1):5-26
2. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life or urinary incontinent women. Br J Obstet Gnaecol 1997;10:1374-9
3. Irwin DE, Milsom I, Hunsaakar S, et al. Population- based survey of urinary incontinence, overactive bladder, and lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006;50:1306-15
4. Reeves P, Irwin D, Kelleher C, et al. The current and future burden cost and cost of the overactive bladder in five European countries. Eur Urol 2006;50(5):1050-7
5. National Institute for Health and Clinical Excellence(2006). Urinary incontinence: The Management of Urinary Incontinence in women. Available from: Http:www.nice.org.uk/ nicemedia/pdf/cg40NICEguidelinepdf
6. Malhotra, Gandelman K, Sachse R, et al. The design and development of fesoterodine as a prodrug of 5-hydroxymeythyl tolterodine (5-HMT)the active metabolite of toterodine. Curr Med Chem 2009;16:4481-9
7. Tubaro A, d De Nunzio C. Comparison of peripherally active substance for treatment of detrusor overactivity: What is new; what is in the pipeline. EAU Update series 2004;2:161
8. Cole P. Fesoterodine an advanced antimuscarinic for the treatment of overactive bladder. A safety update. Drugs Future 2004;29:715
9. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily Fesoterodine in subjects with overactive Bladder. Eur Urol 2007;52(4):1204-12
10. Nitti VW, Dmochowski R, Sand P, et al. Efficacy, safety and tolerability of Fesoterodine for the overactive bladder syndrome. J Urol 2007;178:2488-94
11. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of the overactive bladder: A head-to head placebo-controlled trial. BJU Int 2010;105(1):58-66
12. Toviaz PR. Summary of product characteristics. Pfizer Ltd; 2007
13. A Clinical Summary - Fesoterodine- Pfizer Ltd - December 2008
14. Scarpero H, Sand P, Kelleher C, et al. Long term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Curr Med Res Opin 2011;27(5):921-30